Vertex Pharmaceuticals (VRTX) EBIT Margin (2009 - 2026)
Vertex Pharmaceuticals (VRTX) recorded quarterly EBIT Margin of 38.1% in Q1 2026, up 0.8% quarter-over-quarter from 37.8% in Q4 2025, and up 1536.0% on a YoY basis from 2.33% in Q1 2025.
Vertex Pharmaceuticals (VRTX) EBIT Margin (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' EBIT Margin history runs 18 years deep, the most recent figure standing at 38.1% for Q1 2026.
- In Q1 2026, EBIT Margin rose 1536.0% year-over-year to 38.1%; the TTM figure through Mar 2026 stood at 38.31% (up 4500.0% YoY), while the FY2025 annual figure was 34.77%, up 3689.0% from the prior year.
- EBIT Margin was 38.1% for Q1 2026 at Vertex Pharmaceuticals, up from 37.8% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 50.37% in Q2 2022 to a low of 132.85% in Q2 2024.
- Historically, EBIT Margin has averaged 29.95% across 5 years, with a median of 39.26% in 2023.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin slumped 17402 bps in 2024, then jumped 17168 bps in 2025.
- A 5-year view of EBIT Margin shows it stood at 44.88% in 2022, then slipped by 13 bps to 39.26% in 2023, then slipped by 10 bps to 35.23% in 2024, then gained by 7 bps to 37.8% in 2025, then increased by 1 bps to 38.1% in 2026.
- The last three EBIT Margin figures came in at 38.1% (Q1 2026), 37.8% (Q4 2025), and 38.56% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 17.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.10% |
| Dec 31, 2025 | 37.80% |
| Sep 30, 2025 | 38.56% |
| Jun 30, 2025 | 38.83% |
| Mar 31, 2025 | 22.75% |
| Dec 31, 2024 | 35.23% |
| Sep 30, 2024 | 40.27% |
| Jun 30, 2024 | -132.85% |
| Mar 31, 2024 | 42.35% |
| Dec 31, 2023 | 39.26% |
| Sep 30, 2023 | 41.80% |
| Jun 30, 2023 | 41.17% |
| Mar 31, 2023 | 32.80% |
| Dec 31, 2022 | 44.88% |
| Sep 30, 2022 | 48.27% |
| Jun 30, 2022 | 50.37% |
| Mar 31, 2022 | 49.63% |
| Dec 31, 2021 | 42.35% |
| Sep 30, 2021 | 53.15% |
| Jun 30, 2021 | -2.11% |